{"pmid":32444942,"title":"Are patients with Down syndrome vulnerable to life-threatening COVID-19?","text":["Are patients with Down syndrome vulnerable to life-threatening COVID-19?","Patients with Down syndrome are at increased risk of respiratory syncytial virus- and H1N1-related death. Literature on COVID-19 in Down syndrome patients is unavailable thus far. We describe the clinical course of 4 patients with Down syndrome during an outbreak of COVID-19. In all four patients, disease course was severe, warranting hospital care in three patients, with fatal outcome in one patient. Another patient receives supportive care in our institution. Our case series is the first report on probable increased risk of life-threatening disease course of COVID-19 in patients with Down syndrome. Proper surveillance, the adherence of social distancing, and the use of personal protective equipment will be essential in reducing morbidity and mortality in our patients.","Acta Neurol Belg","De Cauwer, Harald","Spaepen, Ann","32444942"],"abstract":["Patients with Down syndrome are at increased risk of respiratory syncytial virus- and H1N1-related death. Literature on COVID-19 in Down syndrome patients is unavailable thus far. We describe the clinical course of 4 patients with Down syndrome during an outbreak of COVID-19. In all four patients, disease course was severe, warranting hospital care in three patients, with fatal outcome in one patient. Another patient receives supportive care in our institution. Our case series is the first report on probable increased risk of life-threatening disease course of COVID-19 in patients with Down syndrome. Proper surveillance, the adherence of social distancing, and the use of personal protective equipment will be essential in reducing morbidity and mortality in our patients."],"journal":"Acta Neurol Belg","authors":["De Cauwer, Harald","Spaepen, Ann"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32444942","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s13760-020-01373-8","keywords":["covid-19","down syndrome","infection","intellectual disability","pneumonia","viral disease"],"topics":["Case Report"],"weight":1,"_version_":1667600475796537345,"score":9.490897,"similar":[{"pmid":32501455,"pmcid":"PMC7252041","title":"Down Syndrome and COVID-19: A Perfect Storm?","text":["Down Syndrome and COVID-19: A Perfect Storm?","People with Down syndrome show signs of chronic immune dysregulation, including a higher prevalence of autoimmune disorders, increased rates of hospitalization during respiratory viral infections, and higher mortality rates from pneumonia and sepsis. At the molecular and cellular levels, they show markers of chronic autoinflammation, including interferon hyperactivity, elevated levels of many inflammatory cytokines and chemokines, and changes in diverse immune cell types reminiscent of inflammatory conditions observed in the general population. However, the impact of this immune dysregulation in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and CoV disease of 2019 (COVID-19) remains unknown. This Perspective outlines why individuals with Down syndrome should be considered an at-risk population for severe COVID-19. Specifically, the immune dysregulation caused by trisomy 21 may result in an exacerbated cytokine release syndrome relative to that observed in the euploid population, thus justifying additional monitoring and specialized care for this vulnerable population.","Cell Rep Med","Espinosa, Joaquin M","32501455"],"abstract":["People with Down syndrome show signs of chronic immune dysregulation, including a higher prevalence of autoimmune disorders, increased rates of hospitalization during respiratory viral infections, and higher mortality rates from pneumonia and sepsis. At the molecular and cellular levels, they show markers of chronic autoinflammation, including interferon hyperactivity, elevated levels of many inflammatory cytokines and chemokines, and changes in diverse immune cell types reminiscent of inflammatory conditions observed in the general population. However, the impact of this immune dysregulation in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and CoV disease of 2019 (COVID-19) remains unknown. This Perspective outlines why individuals with Down syndrome should be considered an at-risk population for severe COVID-19. Specifically, the immune dysregulation caused by trisomy 21 may result in an exacerbated cytokine release syndrome relative to that observed in the euploid population, thus justifying additional monitoring and specialized care for this vulnerable population."],"journal":"Cell Rep Med","authors":["Espinosa, Joaquin M"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501455","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.xcrm.2020.100019","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668804508702998528,"score":141.27763},{"pmid":32343968,"pmcid":"PMC7195070","title":"Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.","text":["Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.","Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China. Since then, COVID-19 has become a pandemic affecting more than 1.5 million people worldwide. Patients with COVID-19 have a wide spectrum of manifestations, one being cytokine release syndrome (CRS) and its fatal correlate, secondary hemophagocytic lymphohistiocytosis (sHLH). Anti-cytokine therapy such as tocilizumab, an IL-6 receptor antagonist, is a potential treatment for COVID-19; however, data regarding the efficacy of this anti-IL-6 therapy are currently lacking. We report two cases of patients who received a diagnosis of COVID-19 complicated by CRS and were treated with tocilizumab. Both patients progressed to sHLH despite treatment with tocilizumab, and one developed viral myocarditis, challenging the safety and clinical usefulness of tocilizumab in the treatment of COVID-19-induced CRS. These cases highlight the need for clinical trials to determine optimal patient selection and timing for the use of tocilizumab during this disease process.","Chest","Radbel, Jared","Narayanan, Navaneeth","Bhatt, Pinki J","32343968"],"abstract":["Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China. Since then, COVID-19 has become a pandemic affecting more than 1.5 million people worldwide. Patients with COVID-19 have a wide spectrum of manifestations, one being cytokine release syndrome (CRS) and its fatal correlate, secondary hemophagocytic lymphohistiocytosis (sHLH). Anti-cytokine therapy such as tocilizumab, an IL-6 receptor antagonist, is a potential treatment for COVID-19; however, data regarding the efficacy of this anti-IL-6 therapy are currently lacking. We report two cases of patients who received a diagnosis of COVID-19 complicated by CRS and were treated with tocilizumab. Both patients progressed to sHLH despite treatment with tocilizumab, and one developed viral myocarditis, challenging the safety and clinical usefulness of tocilizumab in the treatment of COVID-19-induced CRS. These cases highlight the need for clinical trials to determine optimal patient selection and timing for the use of tocilizumab during this disease process."],"journal":"Chest","authors":["Radbel, Jared","Narayanan, Navaneeth","Bhatt, Pinki J"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343968","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.chest.2020.04.024","keywords":["covid-19","critical care","cytokines","viral disease"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138495811321859,"score":130.65726},{"pmid":32445330,"title":"Time, distance, shielding and ALARA; drawing similarities between measures for radiation protection and Coronavirus disease pandemic response.","text":["Time, distance, shielding and ALARA; drawing similarities between measures for radiation protection and Coronavirus disease pandemic response.","The practice of radiation oncology requires stringent adherence to specific steps and principles designed to minimize exposure of an individual to unnecessary doses of radiation. The basic principles of such measures to reduce the risk of exposure and limit the doses of irradiation follow the \"as low as reasonably achievable \" or ALARA principle by using the concepts of time, distance and shielding. Potential exposures in radiation oncology are controlled through combination of optimal design and installation of radiation delivery equipment with well-defined standard operating procedures (SOPs). In the modern era of viral pandemics, similar principles can also be applied toward prevention of viral transmission and protection of populations at risk. In the ongoing COVID-19 pandemic, the probability of an individual getting infected is dependent on the viral load that an individual is exposed to in public spaces over a period of time. All prevention and control measures are based on preventing any such exposure to the virus, that can be achieved through limiting space for movement of the virus, using barriers and increasing distance to vulnerable surfaces, and limiting the duration of exposure. Apart from adhering to the laid-down provisions of a lock-down, preventive measures recommended for the general public include maintaining hand-hygiene, social distancing, and using facemasks to break the chain of transmission. Appropriate triage and customization of treatment protocols can help curtail hospital visits and time-spent by cancer patients during pandemic times, thereby reducing their risk of exposure as well as allowing efficient utilization of resources. The outbreak of the contagious COVID-19 pandemic threatens to disrupt healthcare systems globally with its unprecedented challenges. However, despite all the difficulties and hardships, it has also enabled new ways of learning and communication, which are likely to persist even in the post-COVID world.","Indian J Cancer","Mukherji, Ashutosh","Gupta, Tejpal","Agarwal, Jai Prakash","32445330"],"abstract":["The practice of radiation oncology requires stringent adherence to specific steps and principles designed to minimize exposure of an individual to unnecessary doses of radiation. The basic principles of such measures to reduce the risk of exposure and limit the doses of irradiation follow the \"as low as reasonably achievable \" or ALARA principle by using the concepts of time, distance and shielding. Potential exposures in radiation oncology are controlled through combination of optimal design and installation of radiation delivery equipment with well-defined standard operating procedures (SOPs). In the modern era of viral pandemics, similar principles can also be applied toward prevention of viral transmission and protection of populations at risk. In the ongoing COVID-19 pandemic, the probability of an individual getting infected is dependent on the viral load that an individual is exposed to in public spaces over a period of time. All prevention and control measures are based on preventing any such exposure to the virus, that can be achieved through limiting space for movement of the virus, using barriers and increasing distance to vulnerable surfaces, and limiting the duration of exposure. Apart from adhering to the laid-down provisions of a lock-down, preventive measures recommended for the general public include maintaining hand-hygiene, social distancing, and using facemasks to break the chain of transmission. Appropriate triage and customization of treatment protocols can help curtail hospital visits and time-spent by cancer patients during pandemic times, thereby reducing their risk of exposure as well as allowing efficient utilization of resources. The outbreak of the contagious COVID-19 pandemic threatens to disrupt healthcare systems globally with its unprecedented challenges. However, despite all the difficulties and hardships, it has also enabled new ways of learning and communication, which are likely to persist even in the post-COVID world."],"journal":"Indian J Cancer","authors":["Mukherji, Ashutosh","Gupta, Tejpal","Agarwal, Jai Prakash"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445330","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.4103/ijc.IJC_343_20","keywords":["coronavirus","exposure","protection","radiation","shielding"],"topics":["Prevention"],"weight":1,"_version_":1667600475859451904,"score":130.34424},{"pmid":32425658,"pmcid":"PMC7228692","title":"Modeling the effects of intervention strategies on COVID-19 transmission dynamics.","text":["Modeling the effects of intervention strategies on COVID-19 transmission dynamics.","Objectives: To model the effects of continuous, intermittent, and stepping-down social distancing (SD) strategies and personal protection measures on COVID-19 transmission dynamics. Methods: Constant, intermittent, and stepping-down SD strategies were modeled at 4 mean magnitudes (5%, 10%, 15% and 20%), 2 time windows (40-days, 80-days), and 2 levels of personal caution (30% and 50%). Results: The stepping-down strategy was the best long-term SD strategy to minimize the peak number of active COVID-19 cases and associated deaths. The stepping-down strategy also resulted in a reduction in total time required to SD over a two-year period by 6.5% compared to an intermittent or constant SD strategy. An 80-day SD time-window was statistically more effective in maintaining control over the COVID-19 pandemic than a 40-day window. However, the results were dependent upon 50% of people being cautious (engaging in personal protection measures). Conclusion: If people exercise caution while in public by protecting themselves (e.g., wearing a facemask, proper hand hygiene and avoid agglomeration) the magnitude and duration of SD necessary to maintain control over the pandemic can be reduced. Our models suggest that the most effective way to reduce SD over a two-year period is a stepping-down approach every 80 days. According to our model, this method would prevent a second peak and the number of intensive care units needed per day would be within the threshold of those currently available.","J Clin Virol","Kennedy, Deanna M","Zambrano, Gustavo Jose","Wang, Yiyu","Neto, Osmar Pinto","32425658"],"abstract":["Objectives: To model the effects of continuous, intermittent, and stepping-down social distancing (SD) strategies and personal protection measures on COVID-19 transmission dynamics. Methods: Constant, intermittent, and stepping-down SD strategies were modeled at 4 mean magnitudes (5%, 10%, 15% and 20%), 2 time windows (40-days, 80-days), and 2 levels of personal caution (30% and 50%). Results: The stepping-down strategy was the best long-term SD strategy to minimize the peak number of active COVID-19 cases and associated deaths. The stepping-down strategy also resulted in a reduction in total time required to SD over a two-year period by 6.5% compared to an intermittent or constant SD strategy. An 80-day SD time-window was statistically more effective in maintaining control over the COVID-19 pandemic than a 40-day window. However, the results were dependent upon 50% of people being cautious (engaging in personal protection measures). Conclusion: If people exercise caution while in public by protecting themselves (e.g., wearing a facemask, proper hand hygiene and avoid agglomeration) the magnitude and duration of SD necessary to maintain control over the pandemic can be reduced. Our models suggest that the most effective way to reduce SD over a two-year period is a stepping-down approach every 80 days. According to our model, this method would prevent a second peak and the number of intensive care units needed per day would be within the threshold of those currently available."],"journal":"J Clin Virol","authors":["Kennedy, Deanna M","Zambrano, Gustavo Jose","Wang, Yiyu","Neto, Osmar Pinto"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425658","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jcv.2020.104440","keywords":["covid-19","compartmental model","intervention strategies","mathematical modeling","pandemic"],"topics":["Prevention"],"weight":1,"_version_":1667252837830098947,"score":122.50565},{"pmid":32470888,"title":"Modeling the effects of intervention strategies on COVID-19 transmission dynamics.","text":["Modeling the effects of intervention strategies on COVID-19 transmission dynamics.","OBJECTIVES: To model the effects of continuous, intermittent, and stepping-down social distancing (SD) strategies and personal protection measures on COVID-19 transmission dynamics. METHODS: Constant, intermittent, and stepping-down SD strategies were modeled at 4 mean magnitudes (5%, 10 %, 15 % and 20 %), 2 time windows (40-days, 80-days), and 2 levels of personal caution (30 % and 50 %). RESULTS: The stepping-down strategy was the best long-term SD strategy to minimize the peak number of active COVID-19 cases and associated deaths. The stepping-down strategy also resulted in a reduction in total time required to SD over a two-year period by 6.5 % compared to an intermittent or constant SD strategy. An 80-day SD time-window was statistically more effective in maintaining control over the COVID-19 pandemic than a 40-day window. However, the results were dependent upon 50 % of people being cautious (engaging in personal protection measures). CONCLUSION: If people exercise caution while in public by protecting themselves (e.g., wearing a facemask, proper hand hygiene and avoid agglomeration) the magnitude and duration of SD necessary to maintain control over the pandemic can be reduced. Our models suggest that the most effective way to reduce SD over a two-year period is a stepping-down approach every 80 days. According to our model, this method would prevent a second peak and the number of intensive care units needed per day would be within the threshold of those currently available.","J Clin Virol","Kennedy, Deanna M","Zambrano, Gustavo Jose","Wang, Yiyu","Neto, Osmar Pinto","32470888"],"abstract":["OBJECTIVES: To model the effects of continuous, intermittent, and stepping-down social distancing (SD) strategies and personal protection measures on COVID-19 transmission dynamics. METHODS: Constant, intermittent, and stepping-down SD strategies were modeled at 4 mean magnitudes (5%, 10 %, 15 % and 20 %), 2 time windows (40-days, 80-days), and 2 levels of personal caution (30 % and 50 %). RESULTS: The stepping-down strategy was the best long-term SD strategy to minimize the peak number of active COVID-19 cases and associated deaths. The stepping-down strategy also resulted in a reduction in total time required to SD over a two-year period by 6.5 % compared to an intermittent or constant SD strategy. An 80-day SD time-window was statistically more effective in maintaining control over the COVID-19 pandemic than a 40-day window. However, the results were dependent upon 50 % of people being cautious (engaging in personal protection measures). CONCLUSION: If people exercise caution while in public by protecting themselves (e.g., wearing a facemask, proper hand hygiene and avoid agglomeration) the magnitude and duration of SD necessary to maintain control over the pandemic can be reduced. Our models suggest that the most effective way to reduce SD over a two-year period is a stepping-down approach every 80 days. According to our model, this method would prevent a second peak and the number of intensive care units needed per day would be within the threshold of those currently available."],"journal":"J Clin Virol","authors":["Kennedy, Deanna M","Zambrano, Gustavo Jose","Wang, Yiyu","Neto, Osmar Pinto"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470888","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jcv.2020.104440","keywords":["covid-19","compartmental model","intervention strategies","mathematical modeling","pandemic"],"topics":["Prevention","Transmission"],"weight":1,"_version_":1668167109980454912,"score":122.50565}]}